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Introduction
Antiphospholipid syndrome (APS) is characterized by
thrombosis and pregnancy loss that occur in the pres-
ence of antiphospholipid (aPL) Ab’s (1). Over the last
two decades, APS has emerged as a leading cause of
pregnancy loss and pregnancy-related morbidity. It is
now recognized that recurrent miscarriage occurs in 1%
of couples (2–4) and that up to 20% of women with
recurrent miscarriage have aPL Ab’s. In the majority of
these otherwise normal women, aPL Ab’s are the sole
explanation for fetal loss (5, 6). The primary treatment
for these patients, anticoagulation throughout preg-
nancy, is fraught with potential complications, includ-
ing hemorrhage and osteoporosis. Moreover, treatment
can prove to be ineffective. Identification of the mecha-
nisms of pregnancy loss in women with aPL Ab’s would
permit development of safer and more effective thera-
pies. Here we identify blockade of the receptor for a pro-
teolytic fragment of complement component 5a (C5a)
as a particularly effective treatment in mice and a poten-
tially important target for treatment of patients.
Several murine models have been developed to study
mechanisms of fetal loss in APS. In one model, passive
transfer of human IgG isolated from aPL Ab–positive
sera from women with recurrent fetal loss, as well as
murine and human monoclonal aPL Ab’s, induce fetal
loss and growth restriction in pregnant mice, demon-
strating the direct pathogenic role of aPL Ab’s (7–10).
While the specific antigenic reactivity of aPL Ab’s is
critical for their effects, the pathogenic mechanisms
that mediate aPL Ab–induced vascular thrombosis, tis-
sue injury, and recurrent fetal loss remain incomplete-
ly understood (11–14).
We hypothesized that complement activation is a
necessary in vivo intermediary step for the clinically rel-
evant deleterious effects of aPL Ab’s on endothelial and
inflammatory cells, platelets, and trophoblast cells
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within the placenta. We investigated this mechanism
because it is well established that activated comple-
ment fragments themselves have the capacity to bind
and activate inflammatory and endothelial cells as well
as to induce a prothrombotic phenotype (15, 16). The
validity of this hypothesis was demonstrated in our
recent studies showing that in the murine model of
APS, blockade of C3 activation prevents fetal loss and
growth restriction induced by passive aPL Ab transfer
(17). Nevertheless, the effectors of tissue injury, the role
of individual complement activation pathways, and the
precise targets for treatment have remained unknown.
In addition to causing complement activation, aPL
Ab’s may induce injury through inflammatory pathways
involving activating Fcγ receptors (FcγRs) and neu-
trophils. These mediators could also link production of
pathogenic IgG to development of overt clinical disease.
In the current work we examined these three mecha-
nisms to determine their relative importance in aPL
Ab–mediated fetal loss. The results of these studies pro-
vide a conceptual framework within which rational ther-
apeutic strategies and interventions can be developed.
Methods
Mice. Adult mice (2–3 months old) were used in all
experiments. BALB/c mice were purchased from
Taconic Farms (Germantown, New York, USA). FcRγ–/–
mice backcrossed to BALB/c mice were provided by Jef-
frey Ravetch (Rockefeller University, New York, New
York, USA) (18). C4–/– mice were generated by homol-
ogous recombination and backcrossed to C57BL/6 for
17 generations (19, 20). C5–/– (B10.D2-H2dH2-T18c
Hco/o2Sn) and the C5+/+ background-strain mice
(B10.D2-H2dH2-T18c Hco/oSnJ) were obtained from
The Jackson Laboratories (Bar Harbor, Maine, USA).
C5a receptor–deficient (C5aR-deficient) mice were
generated by targeted deletion of the murine C5aR
gene and determined to be completely C5aR deficient
by PCR, Northern blot, and immunohistochemistry
analyses (T.J. Hollman and R.A. Wetsel, data not
shown). C5aR-deficient animals were backcrossed with
C57BL/6J mice. Heterozygous C5aR+/– backcrossed
mice were interbred, and the resulting C5aR+/+ and
C5aR–/– littermates were used for studies. Mice defi-
cient in factor B (fB) were generated by targeted dele-
tion (21). The fB–/– mice were generated by intercross-
ing of fB+/– and then maintained as a homozygous
deficient strain. Procedures that involved mice were
approved by the local Committee on Animal Use in
Research and Education and were conducted in strict
accordance with guidelines for the care and use of lab-
oratory research animals promulgated by the NIH.
Preparation of aPL and other Ab’s. Human IgG contain-
ing aPL Ab’s (aPL-IgG) were obtained from three
patients with APS characterized by high-titer aPL Ab’s
(>140 GPL units), thromboses, and/or pregnancy losses
(1). IgG was purified by affinity chromatography using
protein G-Sepharose chromatography columns (Amer-
sham Pharmacia Biotech, Piscataway, New Jersey, USA).
Human IgG from healthy non-autoimmune individ-
uals (NH-IgG) was purified by an identical method.
All IgG samples were treated to deplete endotoxin
with Centriprep ultracentrifugation devices (Milli-
pore Corp., Bedford, Massachusetts, USA) and deter-
mined to be free of endotoxin using the limulus ame-
bocyte lysate assay. F(ab)′2 fragments were obtained
by digestion of purified aPL-IgG pooled from patients
2 and 3 using immobilized pepsin (Pierce Chemical
Co., Rockford, Illinois, USA). The digested super-
natants were passed through protein G-Sepharose to
remove remaining intact IgG, and their purity was
assessed by Western blot analysis using an Ab specif-
ic for the F(ab)′2 fragment (Jackson ImmunoResearch
Laboratories Inc., West Grove, Pennsylvania, USA).
The F(ab)′2 fragments were demonstrated to have aPL
reactivity similar to the intact aPL-IgG by using
ELISA (Sigma-Aldrich, St. Louis, Missouri, USA). The
generation, structure, and specificity of the human
IgG1 mAb’s aPL (mAb 519), anti-DNA (mAb 412.67),
and anti-rabies virus (mAb 57) were previously
described (10, 22–24).
Murine pregnancy model. Females were mated with pre-
viously isolated males. The presence of a vaginal plug
defined day 0 of pregnancy. On days 8 and 12 of preg-
nancy, mice were treated with intraperitoneal injections
of aPL-IgG (10 mg), aPL-IgG F(ab)′2 (10 mg), NH-IgG
(10 mg), and human mAb’s (aPL, anti-DNA, or anti-
rabies) (1 mg) (7, 17). To inhibit C5, mice were treated
on days 8 and 10 of pregnancy with anti-C5 mAb (1 mg,
intraperitoneally) or murine IgG as a control (25). To
block C5aR, mice received a C5aR antagonist peptide
(AcPhe[L-ornithine-Pro-D-cyclohexylalanine-Trp-Arg])
(50 µg) on day 8, 30 minutes before treatment with
aPL-IgG (26, 27). To deplete neutrophils, mice were
treated on day 7 with rat anti-mouse granulocyte RB6-
8C5 mAb (PharMingen, San Diego, California, USA)
(100 µg, intraperitoneally) that reacts with Ly6G (Gr-1
myeloid differentiation antigen); an IgG2b mAb was
the isotype control. The level of Ly6G antigen expres-
sion in bone marrow correlates with granulocyte mat-
uration, and in peripheral blood, rat anti-mouse gran-
ulocyte RB6-8C5 mAb recognizes neutrophils and
eosinophils (28–30). Neutrophil depletion was ob-
served 24 hours after administration of anti-mouse
granulocyte mAb (anti-Gr) and persisted through day
15. Mice were sacrificed on day 15 of pregnancy, uteri
were dissected, fetuses and placentas were weighed, and
fetal resorption rates were calculated (number of
resorptions per total number of formed fetuses and
resorptions). Resorption sites are easily identified and
result from loss of a previously viable fetus. Function-
al C3 activity in serum was measured using the previ-
ously described zymosan assay (31).
Immunohistochemistry. Deciduas were removed from
mice on day 8 of pregnancy, 60 minutes after adminis-
tration of aPL-IgG, frozen in OCT compound, and cut
into 10-µm sections. After quenching endogenous per-
oxidase with 1% H2O2 in methanol and blocking non-
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specific binding sites with normal goat serum (Cappel,
ICN Pharmaceuticals, Aurora, Ohio, USA), sections
were incubated with goat anti-mouse C3, goat anti-
human IgG (Cappel, ICN Pharmaceuticals), or goat
anti-human F(ab′)2 (Jackson ImmunoResearch Labo-
ratories Inc.), followed by anti-goat IgG conjugated to
HRP (Sigma-Aldrich). To detect infiltrating granulo-
cytes, sections were incubated with rat anti-mouse
granulocyte RB6-8C5 mAb (PharMingen), followed by
rabbit anti-rat IgG conjugated to HRP (Sigma-Aldrich).
Bound HRP was detected with 3,3-diaminobenzidine
(DAB). Sections were counterstained with hematoxylin.
The intensity of staining of C3 within decidual and
embryo tissue was scored on a semiquantitative scale (0
to 5+) by three observers who were blinded to the exper-
imental condition. Data are expressed as the mean of
5–8 mice for each experimental condition. Sections of
frozen tissue were also stained with H&E.
Western blot analysis. Deciduas, including embryos,
were removed from mice on day 8 of pregnancy, 60
minutes after administration of aPL-IgG, and immedi-
ately frozen at –70°C. The tissue was homogenized in
RIPA lysis buffer containing 1% Triton X-100, 0.5%
deoxycholic acid, 150 mM NaCl, 20 mM β-glyc-
erophosphate, 20 mM Tris-HCl (pH 8.0), 5 mM EGTA,
3 mM MgCl2, 0.1% SDS, 1 mM DTT, 50 µM Na3VO4,
and EDTA-free protease inhibitor cocktail (Roche
Applied Science, Penzberg, Germany). Lysates (50 µg/
sample) were resolved by electrophoresis with a 10%
Bis-Tris polyacrylamide gel (Invitrogen Corp., Carlsbad,
California, USA) and transferred to a nitrocellulose
membrane. The membrane was probed with HRP-con-
jugated goat anti-mouse C3 (Cappel, ICN Pharmaceu-
ticals) and was visualized using a chemiluminescence
detection kit (Amersham International, Amersham,
United Kingdom). The proteolytic cleavage product
C3-α′ band was identified by comparing serum incu-
bated with or without zymosan.
Statistical analyses. Data are expressed as mean ± SD.
A Student’s t test was used to compare fetal resorption
rates and fetal weights between groups. A Mann-Whit-
ney U test was used to compare values for semiquan-
titative scoring of immunohistochemistry. P values of
less than 0.05 were used to reject the null hypothesis.
Results
Activating FcγRs are not required for aPL Ab–induced preg-
nancy complications. The Fc domain of pathogenic IgG
may initiate tissue damage by binding FcγR on effec-
tor cells and/or initiating activation of complement.
As a first approach to determine the role of FcγR in
pregnancy loss induced by aPL Ab’s we compared the
consequences of treating pregnant mice with poly-
clonal IgG isolated from APS patients and F(ab)′2
fragments prepared from the same IgG source. Passive
transfer of IgG from three different patients with
high-titer aPL Ab’s (aPL-IgG) (>140 GPL units) con-
sistently caused a fourfold increase in the frequency
of fetal resorption (Figure 1a). In contrast, treatment
with F(ab)′2 fragments of aPL-containing IgG did not
Figure 1
Activating FcγRs are not required for aPL Ab–mediated pregnancy loss. Pregnant FcRγ+/+ and FcRγ–/– mice were treated with IgG from a
healthy non-autoimmune individual (NH-IgG), three different patients with APS (aPL-IgG1, aPL-IgG2, aPL-IgG3), F(ab)′2 fragments from a
pool of aPL-IgG from patients 2 and 3 [aPL-F(ab)′2], or human monoclonal aPL Ab (aPL mAb) on days 8 and 12 of pregnancy. Mice were
sacrificed on day 15 of pregnancy, fetuses were weighed, and frequency of fetal resorption calculated (n = 4–7 mice/group). (a) Treatment
with all intact aPL-IgG preparations and aPL mAb caused an increase in fetal resorptions in FcRγ+/+. *P < 0.05 versus NH-IgG, Student’s 
t test. Administration of aPL-F(ab)′2 did not affect pregnancy outcome. FcRγ–/– mice were not protected from fetal loss induced by intact
aPL-IgG. *P < 0.05 versus NH-IgG, Student’s t test). In surviving fetuses from FcRγ –/– mice there was 36% decrease in weight. (b–e) Immuno-
histochemical analysis of decidual tissue from day 8 of pregnancy. Sections were stained with goat anti-human IgG, the chromogen was
DAB (brown), and the counterstain was hematoxylin. Human IgG was deposited in deciduas from FcRγ+/+ mice within 60 minutes of admin-
istration of aPL-IgG (b) or aPL-F(ab)′2 (c), whereas no IgG was detected in deciduas from FcRγ+/+ mice treated with NH-IgG (d). Deposi-
tion of human IgG was similar after treatment with aPL-IgG in FcRγ–/– (e) and FcRγ+/+ mice (b). Data are representative of observations from
three to six decidua from mice in each experimental group. Original magnification was ×200.
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affect the frequency of fetal loss (Figure 1a). Fetal loss
in mice treated with F(ab)′2 fragments of aPL-IgG was
similar to that observed in mice treated with NH-IgG
(Figure 1a). In addition, growth restriction induced by
treating pregnant mice with intact aPL-IgG was also
absent in surviving fetuses of mice treated with aPL-
IgG F(ab)′2 [average fetal weight: aPL-IgG, 213 ± 42
mg; aPL-IgG F(ab)′2, 343 ± 43 mg; NH-IgG, 326 ± 32
mg; aPL-IgG F(ab)′2 versus aPL-IgG, P < 0.05]. Impor-
tantly, deposition of human F(ab)′2 IgG in decidual
tissues was similar in mice treated with aPL-IgG and
aPL-IgG F(ab)′2 (Figures 1, b and c), and no human
IgG deposition was observed in deciduas from mice
treated with NH-IgG (Figure 1d).
Given our finding that the Fc portion of IgG is nec-
essary for aPL Ab–mediated injury, we considered the
possibility that aPL Ab’s deposited in the decidua initi-
ate inflammation, thrombosis, and fetal demise by
cross-linking stimulatory FcγRs expressed on mono-
cytes, neutrophils, platelets, or mast cells. To examine
the role of the FcγR in aPL Ab-induced pregnancy loss,
we studied mice with targeted deletion of the common
γ subunit (FcRγ–/–) that is required for signaling by acti-
vating FcγRs, high-affinity FcγRI, and low-affinity
FcγRIII (18). Although FcRγ-deficient mice are report-
ed to have less-severe or undetectable Ab-dependent
experimental hemolytic anemia, thrombocytopenia,
and glomerulonephritis (32), we found that FcRγ–/–
mice were not protected from poor pregnancy out-
comes after passive transfer of aPL-IgG (Figure 1a). To
exclude the possibility that FcRγ deficiency altered the
localization of aPL-IgG, we performed immunohisto-
chemical analyses of deciduas from FcRγ +/+ and FcRγ –/–
at day 8 of pregnancy (harvested 60 minutes after treat-
ment with aPL-IgG). Comparable amounts of human
IgG were present in FcRγ-sufficient and FcRγ-deficient
mice (Figures 1, b and e). Thus, in our murine model of
APS, aPL-IgG targeted to the placenta can initiate fetal
damage in the absence of activating FcγRs, while F(ab)′2
fragments of aPL-IgG do not mediate such injury.
Blockade of C4 or C5 activation protects mice from aPL
Ab–induced pregnancy loss. The complement pathway
presents a second Fc-dependent means of effecting Ab-
mediated injury, and our initial studies showed that
blocking C3 prevents fetal loss in murine APS (17). To
assess the importance of the classical pathway of com-
plement activation, we treated pregnant C4-deficient
mice with aPL-IgG. C4–/– mice were protected from fetal
loss (Figure 2a) and growth restriction (average fetal
weight in aPL-IgG–treated mice: C4+/+ versus C4–/–
248 ± 19 mg versus 413 ± 30 mg; P < 0.001, n = 5 mice/
group), suggesting that aPL Ab’s trigger the complement
Figure 2
C4 or C5 deficiency prevents aPL Ab–induced fetal loss and growth restriction. (a) Pregnant C4+/+ and C4–/– mice were treated with aPL-
IgG (aPL) (10 mg, intraperitoneally) or NH-IgG on days 8 and 12 of pregnancy, and fetal resorption frequencies were determined on day
15 (n = 5 mice/group). *P < 0.001, aPL versus control. (b–d) Pregnant C5+/+ and C5–/– mice were treated intraperitoneally with aPL-IgG (10
mg), monoclonal human aPL Ab (1 mg), monoclonal human anti-DNA (α-DNA; 1 mg), or their respective controls (NH-IgG or mono-
clonal human anti-rabies Ab, α-R) on days 8 and 12 of pregnancy. Fetal resorption frequencies and fetal weights were determined on day
15 of pregnancy (n = 5–11 mice/group). (b and c) C5–/– mice were protected from fetal loss (b) and growth restriction (c), whereas in the
C5+/+ mice background strain aPL-IgG or aPL mAb caused pregnancy complications. *P < 0.01, aPL versus control. (d) Day 15 fetuses from
C5–/– and C5+/+ mice treated with aPL-IgG. Scale bar: 1 cm.
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cascade through either the classical or lectin pathways.
That the classical pathway is required as an initiator of
complement activation by aPL-IgG is supported by our
finding that F(ab)′2 fragments of aPL-IgG, which lack
the Fc portion necessary to activate the classical path-
way, do not cause pregnancy loss (Figure 1a).
Following initiation of the complement cascade, any
of several complement activation fragment-derived lig-
and-receptor interactions could mediate fetal injury
such as those that we have observed. To define which
elements of the complement cascade mediate preg-
nancy loss, we initially focused on complement com-
ponent 5. C5 is a pivotal member of the complement
system because all three initiating pathways converge
to activate C5 and two effector pathways lead from it.
To determine whether activation of C5 is required for
aPL Ab–induced fetal loss, we treated pregnant C5-defi-
cient and C5-sufficient mice with aPL-IgG, control IgG,
human aPL mAb, human anti-DNA mAb, or control
human IgG1 mAb. In C5+/+ mice, both APS patient-
derived polyclonal aPL-IgG and human aPL mAb
caused a fourfold increase in the frequency of fetal
resorption and a significant decrease in embryo weight
as compared with control IgG (Figure 2, b–d). Treat-
ment with anti-DNA Ab, an autoantibody often pres-
ent in patients with APS, had no effect on pregnancy
outcome. That the results from experiments with
human aPL mAb were similar to results
obtained with polyclonal aPL Ab’s also
indicates that Ab’s reactive with aPL, rather
than xenoreactive Ab’s that may be present
in polyclonal human IgG, are sufficient to
initiate complement activation and fetal
damage in this model.
In contrast to C5+/+ mice, mice lacking
C5 were protected from aPL Ab-induced
pregnancy complications (Figure 2, b–d).
Immunohistochemical analyses of decid-
uas from day 8 of pregnancy obtained 60
minutes after treatment with aPL-IgG,
showed extensive deposition of human
IgG and C3 and focal necrosis and neu-
trophil infiltration in C5+/+ mice (Figure 3,
a and d). In C5–/– mice there were no in-
flammatory infiltrates, and deciduas and
embryos had normal morphology despite
the presence of human IgG within decid-
ual tissue (Figure 3, b and e). Importantly,
in C5–/– mice there was less C3 deposition,
as shown by comparing the representative
sections shown in Figure 3, a and b, and by
grading the intensity of C3 staining in
embryos and decidua from aPL-IgG–treat-
ed mice on a semiquantitative scale of
0–5+ (C5–/– versus C5+/+: 2.5 ± 0.5 versus
4.3 ± 0.6; P < 0.001, n = 5 mice/group).
Taken together, these results demonstrate
that C5 activation is a critical proximal
effector for the induction of fetal loss by
aPL Ab’s and implicate C5 activation and its down-
stream effects in amplifying local C3 deposition.
As an alternative strategy to confirm that C5 activa-
tion is required for fetal loss, we investigated the out-
come of blocking C5 activation with anti-C5 mAb (25).
These experiments may prove particularly relevant
because a similar anti-human C5 mAb is in phase II
studies in patients with rheumatoid arthritis and
phase I studies in patients with active lupus nephritis
(33, 34). We administered anti-C5 mAb before treat-
ment with either NH-IgG or aPL-IgG. The ensuing
blockade of C5 cleavage (35) prevented aPL Ab–
induced pregnancy loss and growth restriction (Figure
4, a and b). Indeed, pregnant mice treated with anti-C5
mAb were protected to an extent similar to C5-defi-
cient mice (Figure 2, b and c, and Figure 4).
C5a-C5aR interactions are critical mediators of aPL
Ab–induced pregnancy complications. Two complement
effector pathways are initiated by cleavage of C5: C5a,
a potent anaphylatoxin and cell activator, and C5b,
which leads to formation of the C5b-9 membrane
attack complex (MAC). We used two methods to dis-
tinguish the role of C5a and the C5aR from that of
MAC seeded by C5b. First, we treated pregnant mice
that had received aPL-IgG with a highly specific pep-
tide antagonist of C5aR, AcPhe[L-ornithine-Pro-D-
cyclohexylalanine-Trp-Arg], which possesses potent in
Figure 3
C5 deficiency limits inflammation, necrosis, and activation of C3 by aPL Ab’s.
Pregnant C5+/+ and C5–/– mice were treated with aPL-IgG (a, b, d, and e) or NH-
IgG (c and f) as described in the legend to Figure 2, and immunohistochemical
analysis was performed on decidual tissue from day 8 of pregnancy. (a–c) Detec-
tion of C3 in day-8 deciduas from aPL-IgG– and NH-IgG–treated mice. The decid-
uas were stained with anti-mouse C3, the chromogen was DAB (brown), and the
counterstain was hematoxylin. Decidua from C5+/+ mice (a) had extensive C3 dep-
osition (arrows), inflammatory cell infiltrates, and necrotic fetal debris, whereas
embryos from C5–/– mice (b) treated with aPL-IgG appeared normal, and there was
limited C3 deposition in deciduas at the maternal-fetal interface compared with
that of C5+/+ treated with NH-IgG (c). Original magnification was ×50. (d–f) Detec-
tion of human IgG in deciduas. Sections were stained with goat anti-human IgG,
the chromogen was DAB (brown), and the counterstain was hematoxylin. Within
60 minutes of administering aPL-IgG, human IgG was detectable in deciduas from
C5+/+ mice (d) and C5–/– mice (e), whereas no IgG was detected in deciduas from
C5+/+ mice treated with NH-IgG (f). Data are representative of observations from
three to six mice in each experimental group. Original magnification was ×200.
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vivo anti-inflammatory activities in murine models of
endotoxic shock, renal ischemia-reperfusion injury,
and the Arthus reaction (26, 27, 36, 37). Administration
of C5aR antagonist peptide prevented aPL-Ab–induced
pregnancy loss and growth restriction, but had no
effect on either frequency of fetal resorption or fetal
size in the absence of aPL Ab’s (Figure 5, a and b). Fetal
protection conferred by the C5aR antagonist was com-
parable to that seen with anti-C5 mAb and in mice
lacking C5 (Figures 2 and 4), suggesting that down-
stream pathogenic effects are mediated predominant-
ly by C5a-C5aR interactions. Immunohistological
analysis of decidual tissue from mice treated with aPL-
IgG and C5aR antagonist peptide yielded results simi-
lar to those in C5–/– mice. There was minimal C3 depo-
sition surrounding normal-appearing fetuses and no
evidence of inflammation.
As a second approach to test the hypothesis that C5a-
C5aR interactions mediate aPL-induced pregnancy
complications, we performed studies in mice deficient
in C5aR. In the background strain, C5aR+/+, there was a
fivefold increase in the frequency of fetal resorption
after treatment with aPL-IgG (Figure 5c), whereas, as
predicted by experiments with the C5aR antagonist
Figure 4
Inhibition of C5 activation with anti-C5 mAb prevents aPL
Ab–induced pregnancy complications. (a and b) Pregnant BALB/c
mice were treated with aPL-IgG (10 mg, intraperitoneally) or NH-
IgG (10 mg, intraperitoneally) at days 8 and 12 of pregnancy. Mice
also received either anti-C5 mAb (1 mg, intraperitoneally) or con-
trol murine IgG (Ctrl-mAb; 1 mg, intraperitoneally) on days 8 and
10 (n = 5–11 mice/group). Pregnancies were assessed as described
in the legend for Figure 1. Administration of anti-C5 mAb prevent-
ed fetal resorption (a) and growth restriction (b). *P < 0.05 versus
NH-IgG plus Ctrl-mAb.
Figure 5
Blockade of C5a-C5aR interaction protects pregnancies from aPL Ab–associated injury. (a and b) Pregnant BALB/c mice were given aPL-
IgG (10 mg, intraperitoneally) or NH-IgG (10 mg, intraperitoneally) on days 8 and 12, and some also received C5aR antagonist peptide
(C5aR-AP) (50 µg, intraperitoneally) on day 8, 30 minutes before administration of aPL-IgG (n = 5–11 mice/group). Pregnancy outcomes
were assessed as described in the legend for Figure 1. Treatment with C5aR-AP prevented fetal loss and growth inhibition. #P < 0.01, aPL
versus aPL plus C5aR-AP. (b) Uteri from day 15 of pregnancy. There are two small amnion sacs and five resorptions (*) in the uterus from
an aPL-IgG–treated mouse, while the uterus of a mouse that received aPL-IgG along with C5aR-AP contained normal size amnionic sacs
and no resorptions, similar to that from a mouse treated with NH-IgG. Data are representative of observations in five to seven mice in each
experimental group. Scale bar: 1 cm. (c) The effects of effects of aPL-IgG on pregnancy outcomes in C5aR–/– and C5aR+/+ mice were com-
pared (n = 5–11 mice/group). Pregnant mice were treated with aPL-IgG or NH-IgG as described above. C5aR–/– mice were protected from
aPL-IgG–induced fetal resorption and growth inhibition. †P < 0.05, aPL-IgG versus NH-IgG.
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peptide, aPL-IgG did not increase the frequency of fetal
resorption in C5aR–/– mice (Figure 5c). The protective
effects of the total absence of C5aRs were also observed
when fetal weights were examined (Figure 5c). Taken
together, our experiments with C5aR–/– mice and C5aR
antagonist peptide identify the C5a-C5aR interaction
as a critical effector of aPL Ab–induced injury.
Depletion of neutrophils protects against aPL-induced preg-
nancy complications. C5a is a potent chemotactic factor
and activator of neutrophils. Since we observed neu-
trophil infiltration at sites of fetal resorption and
demonstrated that the C5a-C5aR interaction is neces-
sary for aPL Ab–induced pregnancy loss, we hypothe-
sized that neutrophils were the critical cellular effec-
tors of fetal damage. Indeed, neutrophils have been
implicated as effectors in pathogenic Ab-induced
arthritis and in Ab-independent murine models of
pregnancy loss (38, 39). To examine the relative impor-
tance of these cells in aPL Ab–initiated damage, we
depleted neutrophils on day 7 of pregnancy by treat-
ing mice with rat anti-Gr RB6-8C5; IgG2b Ab served as
the isotype control. In the absence of neutrophils,
treatment with aPL-IgG did not cause pregnancy loss
or growth restriction, nor were there inflammatory
infiltrates within the deciduas (Figure 6, a–e). Fur-
thermore, without neutrophil infiltration (Figure 6,
c–e) there was less C3 deposition, as shown in Figure
6f compared with Figure 6g and by grading intensity
of C3 staining in embryos and decidua from aPL-IgG–
treated mice (anti-Gr versus IgG2b: 2.4 ± 0.7 versus
4.3 ± 0.6; P < 0.001, n = 5 mice/group). These findings
are similar to the limited C3 deposition we observed in
C5–/– mice and in C5aR blockade.
To exclude the possibility that neutrophil depletion
due to treatment with anti-Gr mAb caused comple-
ment consumption, we measured circulating func-
tional C3 levels using a zymosan activation assay before
and after treatment with anti-Gr mAb (n = 4 mice) (31).
Functional C3 measured at nine time points from 6 to
32 hours after anti-Gr treatment ranged from 95% to
107% of pretreatment levels. At no point was there evi-
dence for a significant decrease in C3, indicating pro-
tection against aPL Ab-induced pregnancy loss afford-
ed by anti-Gr mAb treatment is not due to complement
Figure 6
Neutrophil depletion protects mice from aPL Ab–induced pregnancy complications and limits C3 deposition. BALB/c mice received anti-
mouse granulocyte RB6-8C5 mAb (anti-Gr) (100 µg, intraperitoneally) or IgG2b isotype control mAb on day 7 of pregnancy. On days 8 and
12, mice were treated with aPL-IgG or NH-IgG (n = 5–11 mice/group). (a and b) Neutrophil depletion protected mice from (a) fetal resorp-
tion (*P < 0.01, aPL-IgG plus anti-Gr versus aPL-IgG plus IgG2b) and (b) growth restriction (*P < 0.01, aPL-IgG plus anti-Gr versus aPL-IgG
plus IgG2b). (c and d) Histologic sections of deciduas from day 8 of pregnancy were stained with H&E. In deciduas from mice treated with
anti-Gr plus aPL-IgG (c) there were intact embryos (E) and no inflammatory infiltrates, while in deciduas from mice treated with aPL-IgG
plus IgG2b (d) there was extensive neutrophilic infiltration (stained with anti-Gr shown in e) surrounding embryonic debris (ED). Original
magnification was ×400. (e) Immunohistochemistry to detect infiltrating granulocytes in decidua from an aPL-IgG plus IgG2b–treated mouse.
Original magnification was ×1,000. (f and g) Immunohistochemistry for C3 deposition in decidual tissue. Staining for C3 (arrows) was less
intense and limited to the fetal-maternal interface in deciduas from mice that had received anti-Gr before treatment with aPL-IgG (f), com-
pared with that of mice treated with aPL-IgG plus IgG2b (g). In the presence of infiltrating neutrophils, C3 deposits were present through-
out decidual tissue (g), with particularly intense staining at the fetal-maternal interface surrounding the necrotic residual embryonic debris
(arrows). Original magnification was ×400.
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consumption by IgG-opsonized neutrophils. Rather,
our results are consistent with the conclusion that neu-
trophils contribute directly to fetal injury. Thus, while
among its many effects C5a can activate platelets,
endothelial cells, and mononuclear phagocytes, it
appears that C5a-mediated recruitment (and likely acti-
vation) of neutrophils in the placenta is critical for the
development of pregnancy loss and fetal damage.
Alternative pathway of complement activation contributes
to aPL Ab–induced fetal loss. In the absence of neutrophil
infiltration in decidual tissue, whether as a conse-
quence of blockade of C5a-C5aR interactions or neu-
trophil depletion, we observed limited activation of C3
and improved pregnancy outcomes (Figure 3, b and e,
and Figure 6, c and f). It has been suggested that neu-
trophils promote complement deposition by causing
tissue damage that triggers complement activation and
by secreting C3 and/or properdin at sites of inflamma-
tion to amplify complement activation via the alterna-
tive pathway (40, 41). Given the importance of neu-
trophils in our model of APS and their potential role as
activators of the alternative pathway, we examined the
contribution of this pathway of complement activation
in aPL Ab–induced pregnancy loss by performing stud-
ies in mice deficient in fB. We found that fB–/– mice were
protected from fetal resorption and growth restriction
caused by aPL Ab’s. The frequency of pregnancy loss in
fB–/– mice treated with aPL-IgG was comparable to that
observed in mice treated with control IgG (Figure 7a).
In contrast, fetal wastage and growth restriction was
evident in fB+/+ (background strain) mice treated with
aPL-IgG (Figure 7, a and b). Immunohistochemical
analyses showed substantially less C3 deposition in
decidual tissues and embryos from fB–/– mice treated
with aPL Ab’s than in fB+/+ mice, as shown by compar-
ing the representative sections in Figure 7, d and e, and
by grading intensity of C3 staining in embryos and
deciduas (fB–/– versus fB+/+: 2.4 ± 0.5 versus 4.0 ± 0.6; 
P < 0.001, n = 5–7 mice/group). We confirmed the im-
munohistochemistry results with analysis of lysates
from decidual cells by Western blot analysis probed
with anti-mouse C3 (Figure 7f). Taken together, these
findings indicate that the alternative pathway is an
amplifier of complement activation triggered by aPL
Ab’s targeted to the deciduas.
In summary, our results show that factor B, C3, C5,
and C5aR are required for pregnancy complications
triggered by aPL Ab’s and that neutrophils are critical
effector cells in our model of APS. That aPL-IgG can
initiate fetal damage in the absence of activating
FcγRs, but not in the absence of C4, and that F(ab)′2
fragments of aPL-IgG do not mediate such injury,
suggest that initiation of the complement cascade
occurs via the classical pathway. Our observation that
factor B is required for fetal death and that its pres-
ence is associated with increased C3 deposition
Figure 7
The absence of fB protects mice from aPL Ab–induced fetal loss and extensive C3 deposition within deciduas. fB+/+ and fB–/– mice were treat-
ed with aPL-IgG (10 mg, intraperitoneally) or NH-IgG (10 mg, intraperitoneally) on days 8 and 12 of pregnancy. Fetal resorption frequen-
cies and fetal weights were determined on day 15 of pregnancy (n = 4–8 mice/group). (a and b) In contrast to fB+/+ mice, those deficient in
fB were protected from fetal resorption (*P < 0.05, fB+/+ aPL-IgG versus NH-IgG) and growth restriction (P < 0.001, fB+/+ aPL-IgG versus NH-
IgG). (c–e) Immunohistochemistry for C3 deposition in decidual tissue from day 8 of pregnancy following aPL-IgG administration. In decid-
uas from fB+/+ mice treated with NH-IgG (c), there was minimal C3 deposition and an intact embryo (E). In fB+/+ mice treated with aPL-IgG
(d), C3 deposits were present throughout decidual tissue surrounding the necrotic residual embryonic debris (arrows). In contrast, in fB–/–
mice treated with aPL-IgG (e), C3 deposition was limited (arrows) and the embryos remained intact (E). (f) Detection of C3 by Western
blotting. Lysates from deciduas of fB+/+ mice and fB–/– mice were resolved by electrophoresis and blotted with anti-murine C3 Ab. C3 depo-
sition was greater in deciduas from aPL-IgG–treated fB+/+ mice than in fB–/– mice, as evidenced by the presence of the cleaved C3-α′ chain.
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shows, however, that the alternative pathway ampli-
fies local complement activation and also plays a crit-
ical role in the induction of fetal loss.
Discussion
We have shown in a murine model of APS induced by
passive transfer of human aPL Ab’s that complement
activation plays an essential and causative role in fetal
loss and tissue injury and, in contrast to other models
of Ab-mediated disease, that activating FcγRs are not
required for aPL Ab–induced effects. Specifically, we
have identified the proinflammatory sequelae of C5a-
C5aR interactions and the recruitment of neutrophils
as the critical intermediates linking pathogenic aPL
Ab’s to fetal damage. Our conclusions are based on the
fetal protective effects of C5aR deficiency and C5aR
antagonist peptide, the similar findings with anti-C5
mAb and in C5–/– mice, where C5a generation is pre-
vented, and on the effects of neutrophil depletion.
Our observations that C4–/– mice are protected from
aPL Ab–induced pregnancy loss and that F(ab)′2 frag-
ments of aPL-IgG do not cause fetal injury indicate that
the classical pathway is the initiator of complement acti-
vation and is required for tissue damage. Generation of
C5a, through activation of the classical complement
pathway, amplifies the effects of aPL Ab’s targeted to
the placenta. C5a attracts and activates neutrophils,
monocytes, and mast cells, and stimulates the release
of inflammatory mediators, including reactive oxi-
dants, proteolytic enzymes, chemokines, and cytokines,
as well as complement components. Proteases secreted
by inflammatory cells, particularly neutrophils, can
also increase C5a generation by directly cleaving C5
(42), leading to autocrine and paracrine stimulation
and further recruitment of leukocytes.
Depletion of neutrophils prevents aPL Ab–mediated
fetal injury, indicating that these cells are essential
effectors of tissue damage. Although neutrophil re-
cruitment and activation are most likely a direct C5a
effect, we cannot exclude the possibility that they occur
secondarily to C5a-C5aR–mediated activation of mast
cells (43). Mast cells play a critical role in murine arthri-
tis and bullous pemphigoid induced by passive trans-
fer of Ab’s (43, 44). In these Ab-mediated diseases, as in
our model of aPL Ab–mediated fetal loss, C5 and neu-
trophils are required for tissue damage (38, 43, 45, 46).
In addition to myeloid cells, C5aR is expressed on
endothelial cells, where it triggers production of
macrophage inflammatory protein-2, a potent neu-
trophil chemotactic factor, and monocyte chemoat-
tractant protein-1, which recruits monocytes and lym-
phocytes (47, 48). Release of chemokines in the
presence of C5a increases transmigration of neu-
trophils and amplifies inflammatory cell–mediated tis-
Figure 8
Mechanism of aPL Ab–induced fetal damage. APL Ab’s are preferentially targeted to the placenta where they activate complement via the
classical pathway leading to the generation of potent anaphylatoxins and mediators of effector cell activation, particularly C5a. C5a attracts
and activates neutrophils, monocytes, and platelets and stimulates the release of inflammatory mediators, including reactive oxidants, pro-
teolytic enzymes, chemokines, cytokines, and complement factors C3 and properdin. Secretion of C3 and properdin by neutrophils, as well
as the presence of apoptotic and necrotic decidual tissue, may accelerate alternative pathway activation (dashed line), creating a proin-
flammatory amplification loop at sites of leukocyte infiltration that enhances C3 activation and deposition and generates additional C5a.
This results in further influx of neutrophils, inflammation within the placenta, and, ultimately, fetal injury. Depending on the extent of dam-
age, either death in utero or fetal growth restriction ensues.PMN, neutrophil; Mθ, monocyte/macrophage.
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sue damage. C5aR has also been identified on lung,
kidney, and liver parenchymal cells, where it con-
tributes to inflammatory damage (27, 49). Whether
C5aR is expressed by trophoblast cells or natural killer
cells (abundant in deciduas; ref. 50) and whether it
alters their function to impair pregnancy is unknown.
C5a-C5aR interactions can also trigger thrombosis,
the classic pathologic feature of APS. C5aR induces tis-
sue factor expression on monocytes and production of
plasminogen activator inhibitor-1 by mast cells (51). In
a rat model of Ab-mediated thrombotic glomeru-
lonephritis, C5aR blockade prevents thrombus forma-
tion and leukocyte accumulation, and, similar to our
findings, depletion of neutrophils prevents glomerular
thrombosis, despite the presence of C3 and MAC (52).
These studies underscore the link between complement
activation and thrombophilia in inflammatory diseases.
One of our most striking findings is that C3 deposi-
tion in decidual tissue of aPL Ab-treated mice is dimin-
ished in the absence of C5 activation and C5a release. We
observed this phenomenon in mice treated with anti-C5
mAb, mice lacking C5 or C5aR, and mice treated with
C5aR antagonist peptide. While decreased C3 deposition
as a consequence of C5 activation blockade may appear
counterintuitive because C3 activation precedes C5 acti-
vation, we believe this finding is explained by the coinci-
dent inhibition of neutrophil infiltration. In each setting
where C5 activation was blocked, neutrophils were
absent from decidual tissues, and in neutrophil-deplet-
ed mice, C3 deposition was substantially decreased.
Thus, C3 activation and deposition do not appear to be
solely dependent on complement components because
these are ample in the plasma and extracellular fluid;
rather, in the absence of neutrophils, there is limited
amplification of the cascade and cleavage of C3.
Because apoptotic and necrotic cells activate alterna-
tive and classical pathways, neutrophil-induced cell
damage may in and of itself increase C3 deposition in
decidual tissues (53). In addition, neutrophils can
enhance complement activation by releasing comple-
ment components, including C3 and properdin, a crit-
ical positive regulator of the alternative pathway. Prop-
erdin functions by stabilizing the interaction of fB with
spontaneously generated initial C3(H2O) and the for-
mation of the C3 convertase C3bBb (40, 41). Such pos-
itive regulatory activity permits properdin to signifi-
cantly enhance alternative pathway C3 activation
resulting either from initiation of this pathway direct-
ly by C3(H2O) formation or indirectly through the
amplification loop, which uses C3b generated from the
classical pathway C3 convertase C4b2a. Thus, prop-
erdin and C3 secretion by neutrophils may accelerate
alternative pathway activation at sites of leukocyte
infiltration, enhancing C3 activation and deposition
(40). Our results suggest that initial C3 deposition cat-
alyzed by classical pathway activation leads to C5a gen-
eration, attracting neutrophils and potentially trigger-
ing properdin release (Figure 8). Furthermore, the
experiments in the fB–/– mice support the possibility
that properdin and the alternative pathway generate
most C3 at sites of injury and initiate a positive feed-
back loop that generates additional C5a (Figure 8).
The linkage of alternative pathway activation with
neutrophil infiltration may also account for the resist-
ance of mice deficient in fB, C3, C5/C5aR, or neu-
trophils to joint damage after treatment with arthrito-
genic Ab’s, a phenotype that parallels our model (38,
45, 46, 54, 55). There are, however, fundamental differ-
ences in the mechanisms of tissue damage in these two
experimental models of Ab-mediated injury. Arthrito-
genic Ab’s act through both FcγR and C5a, the latter
generated exclusively through the alternative comple-
ment pathway with classical pathway components
entirely dispensable (38, 46). In contrast, our studies
clearly show that fetal injury caused by aPL Ab’s
requires the classical complement pathway as an ini-
tiator and is independent of FcγR. Nonetheless, a com-
mon and unexpected finding emerged in both experi-
mental models — the importance of the alternative
pathway for injury. Our findings are novel in that they
link alternative pathway activation to neutrophil infil-
tration and raise the possibility that infiltrating cells
regulate local complement activation.
That blockade of C5 or C5aR is effective in prevent-
ing fetal injury in APS has important therapeutic
implications. Blocking the complement cascade at C5
inhibits mediators and effectors of tissue injury while
preserving the complement-derived immunoprotec-
tive functions of C3. Complement inhibitors are now
being tested in patients with inflammatory, ischemic,
and autoimmune diseases. Identifying complement-
related markers that predict high risk for fetal loss
will allow us to translate insights about the mecha-
nisms of complement-mediated disease to interven-
tions that may prevent, arrest, or modify the deleteri-
ous effects of aPL Ab’s.
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